{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:54:14Z","timestamp":1787241254372,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ceftolozane\/tazobactam has been developed as a novel carbapenem-sparing agent. Our study aimed at comparing the effectiveness of ceftolozane\/tazobactam versus meropenem for the treatment of bloodstream infections (BSIs) due to ESBL producers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study was conducted at the Laiko General Hospital of Athens from 1 January 2022 to 28 February 2024. Patients with BSIs due to ESBL-producing Enterobacterales were identified using electronic health records. Inverse probability of treatment weighting (IPTW) was used to compare the two treatment modalities. The primary endpoint was 30\u2005day all-cause mortality; secondary endpoints included clinical cure, in-hospital mortality and antibiotic consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 144 patients with ESBL BSIs, of whom 115 were included in our analysis (ceftolozane\/tazobactam, n\u200a=\u200a41 versus meropenem, n\u200a=\u200a74). The mean age was 73.6\u200a\u00b1\u200a14.1\u2005years and 55.7% (64\/115) were male. Persons treated with ceftolozane\/tazobactam were older (78.2\u200a\u00b1\u200a13.3 versus 70.9\u200a\u00b1\u200a14\u2005years, P\u200a=\u200a0.008) and their isolates were more likely to be susceptible to cefoxitin (2.4% versus 21.6%, P\u200a=\u200a0.005). There were no significant differences between the two groups in clinical cure rates (68.3% versus 75.7%, P\u200a=\u200a0.511), in-hospital mortality (34.1% versus 29.7%, P\u200a=\u200a0.677) or 30\u2005day mortality (34.1% versus 29.7%, P\u200a=\u200a0.677). These findings were confirmed by IPTW analysis, which showed no difference between ceftolozane\/tazobactam and the carbapenem for clinical cure (OR 0.43, 95% CI 0.12\u20131.53, P\u200a=\u200a0.193), hospital mortality (OR 1.72, 95% CI 0.54\u20135.51, P\u200a=\u200a0.360) and 30\u2005day mortality (OR 1.72, 95% CI 0.54\u20135.48, P\u200a=\u200a0.357).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftolozane\/tazobactam is a viable alternative to meropenem for the treatment of ESBL BSIs. Prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf229","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:53:44Z","timestamp":1751529224000},"page":"2314-2322","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of ceftolozane\/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-872X","authenticated-orcid":false,"given":"Dimitrios","family":"Basoulis","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Laiko General Hospital , Athens ,","place":["Greece"]},{"name":"Infectious Diseases Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Gkoufa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida","family":"Mastrogianni","sequence":"additional","affiliation":[{"name":"Emergency Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Pantazatou","sequence":"additional","affiliation":[{"name":"Microbiology Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Deliolanis","sequence":"additional","affiliation":[{"name":"Microbiology Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Rigatou","sequence":"additional","affiliation":[{"name":"Microbiology Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Karapanou","sequence":"additional","affiliation":[{"name":"Infection Control Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Zerva","sequence":"additional","affiliation":[{"name":"Infection Control Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N","family":"Gamaletsou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Laiko General Hospital , Athens ,","place":["Greece"]},{"name":"Infectious Diseases Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-9712","authenticated-orcid":false,"given":"Michael","family":"Samarkos","sequence":"additional","affiliation":[{"name":"1st Internal Medicine Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-3453","authenticated-orcid":false,"given":"Nikolaos V","family":"Sipsas","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Laiko General Hospital , Athens ,","place":["Greece"]},{"name":"Infectious Diseases Department, Laiko General Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025080100172613300_dkaf229-B1","author":"ECDC"},{"key":"2025080100172613300_dkaf229-B2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/jac\/dkw513","article-title":"Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"72","author":"Palacios-Baena","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025080100172613300_dkaf229-B3","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025080100172613300_dkaf229-B4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2025080100172613300_dkaf229-B5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/pharmaceutics15020518","article-title":"Correlation between antimicrobial resistance and the hospital-wide diverse use of broad-spectrum antibiotics by the antimicrobial stewardship program in Japan","volume":"15","author":"Ueda","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025080100172613300_dkaf229-B6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2025080100172613300_dkaf229-B7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025080100172613300_dkaf229-B8","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025080100172613300_dkaf229-B9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025080100172613300_dkaf229-B10","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025080100172613300_dkaf229-B11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12941-022-00528-0","article-title":"Ceftolozane\/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)","volume":"21","author":"Khankhel","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025080100172613300_dkaf229-B12","author":"EUCAST"},{"key":"2025080100172613300_dkaf229-B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2025080100172613300_dkaf229-B14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.20411\/pai.v9i2.711","article-title":"Effect of ceftaroline, ceftazidime\/avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam on establishment of colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice","volume":"9","author":"Hausman","year":"2024","journal-title":"Pathog Immun"},{"key":"2025080100172613300_dkaf229-B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13063-021-05206-8","article-title":"Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (\u201cMERINO-3\u201d): study protocol for a multicentre, open-label randomised non-inferiority trial","volume":"22","author":"Stewart","year":"2021","journal-title":"Trials"},{"key":"2025080100172613300_dkaf229-B16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013\u20132015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025080100172613300_dkaf229-B17","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025080100172613300_dkaf229-B18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s10096-024-04756-4","article-title":"Activity of ceftolozane\/tazobactam and imipenem\/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021","volume":"43","author":"Karlowsky","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025080100172613300_dkaf229-B19","doi-asserted-by":"publisher","first-page":"9958678","DOI":"10.1155\/2024\/9958678","article-title":"Relationship between antibiotic consumption and resistance: a systematic review","volume":"2024","author":"Abejew","year":"2024","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2025080100172613300_dkaf229-B20","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/jac\/dkae157","article-title":"Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case\u2013control\u2013control study","volume":"79","author":"Zhou","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025080100172613300_dkaf229-B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jhin.2024.03.003","article-title":"Healthcare-associated carbapenem-resistant Klebsiella pneumoniae infections are associated with higher mortality compared to carbapenem-susceptible K. pneumoniae infections in the intensive care unit: a retrospective cohort study","volume":"148","author":"Yao","year":"2024","journal-title":"J Hosp Infect"},{"key":"2025080100172613300_dkaf229-B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cmi.2023.11.008","article-title":"Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)","volume":"30","author":"Paniagua-Garc\u00eda","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2025080100172613300_dkaf229-B23","doi-asserted-by":"publisher","first-page":"2400317","DOI":"10.2807\/1560-7917.ES.2024.29.46.2400317","article-title":"Measuring hospital antibiotic consumption in EU\/EEA countries: comparison of different metrics, 2017 to 2021","volume":"29","author":"Rubini\u0107","year":"2024","journal-title":"Euro Surveill"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2314\/63717105\/dkaf229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2314\/63717105\/dkaf229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:17:35Z","timestamp":1754021855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/8\/2314\/8196090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf229","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,10]]}}}